Abstract
Background
An association between fibromyalgia and hepatitis C virus (HCV) has been previously described. However, the relationship between nonalcoholic steatohepatitis (NASH) and fibromyalgia symptoms has not been assessed, though they share several risk factors.
Aim
We aimed to assess the factors associated with fibromyalgia symptoms across etiologies of liver disease.
Methods
Patients with cirrhosis due to HCV, NASH, or alcohol were recruited from an outpatient hepatology clinic and administered the Hospital Anxiety and Depression Score, Pittsburgh Sleep Quality Index, and the modified 2010 American College of Rheumatology Diagnostic Criteria for Fibromyalgia. Serum inflammatory markers were measured with standard luminex assays.
Results
Of 193 participants, 53 (27 %) met criteria for fibromyalgia. Fibromyalgia symptoms were significantly associated with etiology of liver disease (HCV: 35 %, NASH: 30 %, alcohol-related liver disease: 12 %, p < 0.01). Using logistic regression, mood symptoms (OR 1.14, 95 % CI 1.06, 1.22), sleep disturbance (OR 1.32, 95 % CI 1.16, 1.52), and etiology of liver disease (NASH vs. HCV not different, alcohol vs. HCV OR 0.19, 95 % CI 0.05, 0.63) were associated with fibromyalgia symptoms. If abdominal pain was included in the model, etiology became nonsignificant, indicating that it may be central sensitization due to abdominal pain in patients with chronic liver disease that explains fibromyalgia symptoms rather than the etiology of liver disease or inflammation.
Conclusions
Fibromyalgia symptoms were significantly associated with HCV and NASH cirrhosis and with psychiatric symptoms. Future work should focus on the underlying pathophysiology and management of widespread pain in patients with cirrhosis.
Similar content being viewed by others
References
Wolfe F. Fibromyalgia wars. J Rheumatol. 2009;36:671–678. doi:10.3899/jrheum.081180.
Cagnie B, Coppieters I, Denecker S, Six J, Danneels L, Meeus M. Central sensitization in fibromyalgia? A systematic review on structural and functional brain MRI. Semin Arthritis Rheum. 2014. doi:10.1016/j.semarthrit.2014.01.001.
Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58:26–35. doi:10.1002/art.23176.
Kozanoglu E, Canataroglu A, Abayli B, Colakoglu S, Goncu K. Fibromyalgia syndrome in patients with hepatitis C infection. Rheumatol Int. 2003;23:248–251. doi:10.1007/s00296-003-0290-7.
Narvaez J, Nolla JM, Valverde-Garcia J. Lack of association of fibromyalgia with hepatitis C virus infection. J Rheumatol. 2005;32:1118–1121.
Moldofsky H. The significance of dysfunctions of the sleeping/waking brain to the pathogenesis and treatment of fibromyalgia syndrome. Rheum Dis Clin North Am. 2009;35:275–283. doi:10.1016/j.rdc.2009.05.008.
Schuh-Hofer S, Wodarski R, Pfau DB, et al. One night of total sleep deprivation promotes a state of generalized hyperalgesia: a surrogate pain model to study the relationship of insomnia and pain. Pain. 2013;154:1613–1621. doi:10.1016/j.pain.2013.04.046.
Diaz-Piedra C, Catena A, Miro E, Pilar Martinez M, Sanchez AI, Buela-Casal G. The impact of pain on anxiety and depression is mediated by objective and subjective sleep characteristics in fibromyalgia patients. Clin. J Pain. 2013. doi:10.1097/AJP.0000000000000040.
Stewart CA, Auger R, Enders FT, Felmlee-Devine D, Smith GE. The effects of poor sleep quality on cognitive function of patients with cirrhosis. J Clin Sleep Med. 2014;10:21–26. doi:10.5664/jcsm.3350.
Uceyler N, Hauser W, Sommer C. Systematic review with meta-analysis: cytokines in fibromyalgia syndrome. BMC Musculoskelet Disord.. 2011;12:245. doi:10.1186/1471-2474-12-245.
Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology. 2003;38:413–419. doi:10.1053/jhep.2003.50316.
Torer N, Ozenirler S, Yucel A, Bukan N, Erdem O. Importance of cytokines, oxidative stress and expression of BCL-2 in the pathogenesis of non-alcoholic steatohepatitis. Scand J Gastroenterol. 2007;42:1095–1101. doi:10.1080/00365520701286680.
Gao B. Hepatoprotective and anti-inflammatory cytokines in alcoholic liver disease. J Gastroenterol Hepatol. 2012;27:89–93. doi:10.1111/j.1440-1746.2011.07003.x.
Miller AM, Horiguchi N, Jeong WI, Radaeva S, Gao B. Molecular mechanisms of alcoholic liver disease: innate immunity and cytokines. Alcohol Clin Exp Res. 2011;35:787–793. doi:10.1111/j.1530-0277.2010.01399.x.
Zampino R, Marrone A, Restivo L, et al. Chronic HCV infection and inflammation: clinical impact on hepatic and extra-hepatic manifestations. World J Hepatol. 2013;5:528–540. doi:10.4254/wjh.v5.i10.528.
Staud R, Rodriguez ME. Mechanisms of disease: pain in fibromyalgia syndrome. Nat Clin Pract Rheumatol. 2006;2:90–98. doi:10.1038/ncprheum0091.
McBeth J, Lacey RJ, Wilkie R. Predictors of new-onset widespread pain in older adults: results from a population-based prospective cohort study in the UK. Arthritis Rheumatol. 2014;66:757–767. doi:10.1002/art.38284.
Rogal SS, Winger D, Bielefeldt K, Szigethy E. Pain and opioid use in chronic liver disease. Dig Dis Sci. 2013;58:2976–2985. doi:10.1007/s10620-013-2638-5.
Rogal SS, Bielefeldt K, Wasan AD, et al. Inflammation, psychiatric symptoms, and opioid use are associated with pain and disability in patients with Cirrhosis. Clin Gastroenterol Hepatol. 2014 (in press).
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–370.
Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res. 2002;52:69–77.
Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28:193–213.
Osorio CD, Gallinaro AL, Lorenzi-Filho G, Lage LV. Sleep quality in patients with fibromyalgia using the Pittsburgh Sleep Quality Index. J Rheumatol. 2006;33:1863–1865.
Buysse DJ, Hall ML, Strollo PJ, et al. Relationships between the Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), and clinical/polysomnographic measures in a community sample. J Clin Sleep Med. 2008;4:563–571.
Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain. 1975;1:277–299.
Wolfe F, Clauw DJ, Fitzcharles MA, et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. J Rheumatol. 2011;38:1113–1122. doi:10.3899/jrheum.100594.
Ferrari R, Russell AS. A questionnaire using the modified 2010 American College of Rheumatology criteria for fibromyalgia: specificity and sensitivity in clinical practice. J Rheumatol. 2013;40:1590–1595. doi:10.3899/jrheum.130367.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383.
Vignali DA. Multiplexed particle-based flow cytometric assays. J Immunol Methods. 2000;243:243–255.
R_Core_Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2012. http://www.R-project.org/.
Thompson ME, Barkhuizen A. Fibromyalgia, hepatitis C infection, and the cytokine connection. Curr Pain Headache Rep. 2003;7:342–347.
Wang H, Buchner M, Moser MT, Daniel V, Schiltenwolf M. The role of IL-8 in patients with fibromyalgia: a prospective longitudinal study of 6 months. Clin J Pain. 2009;25:1–4. doi:10.1097/AJP.0b013e31817e13a3.
Garcia JJ, Cidoncha A, Bote ME, Hinchado MD, Ortega E. Altered profile of chemokines in fibromyalgia patients. Ann Clin Biochem. 2013. doi:10.1177/0004563213506413.
Wang H, Moser M, Schiltenwolf M, Buchner M. Circulating cytokine levels compared to pain in patients with fibromyalgia—a prospective longitudinal study over 6 months. J Rheumatol. 2008;35:1366–1370.
Wallace DJ, Linker-Israeli M, Hallegua D, Silverman S, Silver D, Weisman MH. Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology. 2001;40:743–749.
Choi JC, Lee JH, Choi E, Chung MI, Seo SM, Lim HK. Effects of seasonal differences in testosterone and cortisol levels on pain responses under resting and anxiety conditions. Yonsei Med J. 2014;55:216–223. doi:10.3349/ymj.2014.55.1.216.
Alfven G, de la Torre B, Uvnas-Moberg K. Depressed concentrations of oxytocin and cortisol in children with recurrent abdominal pain of non-organic origin. Acta Paediatr. 1994;83:1076–1080.
Choi JC, Chung MI, Lee YD. Modulation of pain sensation by stress-related testosterone and cortisol. Anaesthesia. 2012;67:1146–1151. doi:10.1111/j.1365-2044.2012.07267.x.
Fede G, Spadaro L, Tomaselli T, et al. Comparison of total cortisol, free cortisol, and surrogate markers of free cortisol in diagnosis of adrenal insufficiency in patients with stable cirrhosis. Clin Gastroenterol Hepatol. 2013. doi:10.1016/j.cgh.2013.08.028.
Aravinthan A, Al-Naeeb Y, Richardson P. Relative adrenal insufficiency in a patient with liver disease. Eur J Gastroenterol Hepatol. 2009;21:381–383. doi:10.1097/MEG.0b013e328309c77e.
Braunersreuther V, Viviani GL, Mach F, Montecucco F. Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol. 2012;18:727–735. doi:10.3748/wjg.v18.i8.727.
Senna MK, Sallam RA, Ashour HS, Elarman M. Effect of weight reduction on the quality of life in obese patients with fibromyalgia syndrome: a randomized controlled trial. Clin Rheumatol. 2012;31:1591–1597. doi:10.1007/s10067-012-2053-x.
Mork PJ, Vasseljen O, Nilsen TI. Association between physical exercise, body mass index, and risk of fibromyalgia: longitudinal data from the Norwegian Nord-Trondelag Health Study. Arthritis Care Res. 2010;62:611–617. doi:10.1002/acr.20118.
Chung M, Wang C. Can alcohol consumption be an alternative treatment for fibromyalgia? Arthritis Res Therapy. 2013;15:126. doi:10.1186/ar4394.
Laird BJ, Scott AC, Colvin LA, et al. Pain, depression, and fatigue as a symptom cluster in advanced cancer. J Pain Symptom Manage. 2011;42:1–11. doi:10.1016/j.jpainsymman.2010.10.261.
Ballantyne JC, Shin NS. Efficacy of opioids for chronic pain: a review of the evidence. Clin J Pain. 2008;24:469–478. doi:10.1097/AJP.0b013e31816b2f26.
Dwyer JP, Jayasekera C, Nicoll A. Analgesia for the Cirrhotic Patient: a literature review and recommendations. J Gastroenterol Hepatol. 2014. doi:10.1111/jgh.12560.
Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev. 2014;1:CD007115. doi:10.1002/14651858.CD007115.pub3.
Acknowledgments
We would like to thank Amy Schmotzer and Sharon Boggiano for their help with this project. This project was supported by the Starzl Transplantation Institute Young Investigator Award, NIH grant T32-DK063922.
Conflict of interest
We have no disclosures relevant to the manuscript, but Dr. Szigethy has received travel support from Merck.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rogal, S.S., Bielefeldt, K., Wasan, A.D. et al. Fibromyalgia Symptoms and Cirrhosis. Dig Dis Sci 60, 1482–1489 (2015). https://doi.org/10.1007/s10620-014-3453-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-014-3453-3